ClinicalTrials.gg
WithdrawnNCT05126966DiagridUpdated Jan 18, 2024

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

A Phase 3 interventional study of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration, sponsored by Hoffmann-La Roche. Withdrawn at 10 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Roche/Genentech has initiated an immediate pause of all new PDS implantations because the implants from commercial supply in the clinical studies did not meet the filed specifications for the intended use

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
121st of 124
0 · median 64
Started
2023
the only one that year
Phase 3
31 of 125
2 open now
Registered
118th of 125
by date
Lead sponsor
5 of 125
Hoffmann-La Roche

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 121st largest by enrollment of the 124 interventional ones that give a count, is the only one that started in 2023, is one of 31 in phase 3, and was the 118th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This study will evaluate the effectiveness and safety of a 36-week refill regimen for the Port Delivery System with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per treat-and-extend (aflibercept T\&E) in subjects with neovascular (wet) age-related macular degeneration (nAMD).

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration

Keywords

  • Wet AMD
  • neovascular AMD
  • exudative AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form
  2. Age ≥ 50 years, at time of signing Informed Consent Form
  3. Ability and willingness to undertake all scheduled visits and assessments
  4. For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use measures

    Ocular Inclusion Criteria:

  5. Initial diagnosis of nAMD within 9 months prior to the screening visit
  6. Previous treatment with at least three anti-VEGF intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit
  7. Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis
  8. Availability of historical visual acuity data obtained at or after nAMD diagnosis and prior to the first anti-VEGF treatment for nAMD
  9. Availability of historical SD-OCT image data obtained at or after nAMD diagnosis and prior to the first anti-VEGF treatment for nAMD
  10. BCVA of 34 letters or better (20/200 or better approximate Snellen equivalent), using ETDRS chart at a starting distance of 4 meters (see the BCVA manual for additional details) at screening and randomization visits
  11. With any subtype of nAMD lesions (i.e., type I, type II, type III, or mixed forms per OCT classification, including polypoidal choroidal vasculopathy and retinal angiomatous proliferation)
  12. Sufficiently clear ocular media and adequate pupillary dilation to allow for clinical examination and analysis and grading by the central reading center of fundus photography (FP), FA, fundus autofluorescence (FAF) image, and SD-OCT images

Exclusion criteria

Exclusion Criteria:

Prior Ocular Treatment - Study Eye

  1. History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
  2. Prior pars plana vitrectomy surgery
  3. Prior treatment with Visudyne® (verteporfin for injection), external-beam radiation therapy, or transpupillary thermotherapy
  4. Previous treatment with intravitreal injection
  5. Previous intraocular device implantation (not including intraocular lens implants)
  6. Previous intraocular surgery (including cataract surgery) within 3 months of randomization
  7. Previous laser (any type) used for AMD or diabetic retinopathy treatment
  8. History of vitreous hemorrhage
  9. History of rhegmatogenous retinal detachment
  10. Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant
  11. History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
  12. History of corneal transplant
  13. History of conjunctival surgery in the superotemporal quadrant (including pterygium surgery)

    Prior Ocular Treatment Either Eye:

  14. History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the ranibizumab or aflibercept injections, study-related procedure preparations (including fluorescein), dilating drops, or any of the anesthetic and antimicrobial preparations used by a subject during the study
  15. Any to aflibercept as per local label
  16. Prior participation in a clinical trial involving any anti-VEGF drugs within 6 months prior to the randomization visit
  17. Prior treatment with brolucizumab (at any time prior to the screening visit)
  18. Prior treatment with external-beam radiation therapy or brachytherapy

    MNV (CNV) Lesion Characteristics Study Eye:

  19. Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5-disc area (1.27 mm\^2) in size at screening
  20. Subfoveal fibrosis or subfoveal atrophy

    MNV (CNV) Lesion Characteristics Either Eye:

  21. CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorio retinopathy, or pathologic myopia
  22. CNV masquerading lesions (e.g., cone dystrophy, adult vitelliform dystrophy, pattern dystrophy)

    Concurrent Ocular Conditions Study Eye :

  23. Subfoveal and/or juxtafoveal retinal pigment epithelial tear
  24. Scleral pathology in the superotemporal quadrant (e.g., scleral thinning or calcification)
  25. Conjunctival pathologies (e.g., pterygium, scarring, thinning, fibrosis) in the superotemporal quadrant
  26. Any concurrent intraocular condition (e.g., cataract, glaucoma, diabetic retinopathy, epiretinal membrane, amblyopia, or strabismus) that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results
  27. Active intraocular inflammation (grade trace or above)
  28. Rhegmatogenous retinal tears or peripheral retinal breaks on depressed fundus exam that are untreated, or treated within 3 months prior to the randomization visit
  29. Aphakia or absence of the posterior capsule Previous violation of the posterior capsule is also an exclusion criterion unless it occurred as a result of yttrium-aluminum garnet (YAG) laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
  30. Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia or evidence of pathologic myopia on depressed fundus exam
  31. Preoperative refractive error that exceeds 8 diopters of myopia, for subjects who have undergone prior refractive or cataract surgery in the study eye
  32. Spherical equivalent of the refractive error demonstrating more than 5 diopters of hyperopia
  33. Preoperative refractive error that exceeds 5 diopters of hyperopia, for subjects who have undergone prior refractive or cataract surgery
  34. Uncontrolled ocular hypertension or glaucoma (defined as intraocular pressure [IOP] > 25 mmHg or a cup to disc ratio > 0.8, despite treatment with anti-glaucoma medication) and any such condition the investigator determines may require a glaucoma-filtering surgery during a subject's participation in the study
  35. History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum, severe dry eye syndrome, or severe allergic conjunctivitis
  36. Ectropion, entropion, ingrowing lashes, or other impairment of the upper or lower eyelid impacting lid functionality needed to protect the ocular surface from exposure
  37. Trichiasis
  38. Corneal neuropathy
  39. Lagophthalmos or incomplete blink
  40. Active or history of facial nerve palsy/paresis

    Concurrent Ocular Conditions Non-Study (Fellow) Eye

  41. Non-functioning non-study eye, defined as either:

    1. BCVA of hand motion or worse
    2. No physical presence of non-study eye (i.e., monocular)
    3. Legally blind in the subject's relevant jurisdiction

    Concurrent Ocular Conditions Either Eye

  42. Any active or history of uveitis (e.g., idiopathic, drug-associated, or -associated uveitis)
  43. Active or history of keratitis, scleritis, endophthalmitis, or chronic blepharitis
  44. Suspected or active ocular or periocular infectious conjunctivitis or endophthalmitis
  45. Active or history of Sjogrens syndrome or keratoconjunctivitis sicca
  46. Active or history of floppy eyelid syndrome
  47. Active or history of chronic eye rubbing
  48. Active thyroid eye disease

    Concurrent Systemic Conditions:

  49. Inability to comply with study schedule or procedures as described in the study protocol
  50. Uncontrolled blood pressure (defined as systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg, while a subject is at rest) If a subject's initial measurement exceeds these values, a second reading should be taken ≥ 30 minutes after the first reading If the subject's blood pressure must be controlled by antihypertensive medication, the subject may become eligible if medication is taken continuously for at least 30 days prior to Day 1
  51. Active or history of autoimmune diseases, for example, rheumatoid arthritis, lupus, granulomatosis with polyangiitis (Wegner's)
  52. History of stroke within the last 3 months prior to
  53. Atrial fibrillation diagnosed or worsened within the last 3 months prior to informed consent
  54. History of myocardial infarction within the last 3 months prior to informed consent
  55. History of other disease, metabolic dysfunction (including uncontrolled diabetes), or clinical laboratory finding (after reviewing the results of the screening laboratory results) giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab, aflibercept, or placement of the implant and that might affect interpretation of the results of the study or renders the subject at high risk of treatment complications in the opinion of the investigator
  56. Confirmed active systemic infection
  57. Use of any systemic anti-VEGF agents
  58. Chronic use of oral corticosteroids (> 10 mg/day of prednisone or equivalent)
  59. Active cancer within 12 months of randomization except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤ 6 and a stable prostate-specific antigen for > 12 months
  60. Previous participation in any non-ocular (systemic) disease studies of drugs within 1 month preceding the informed consent (excluding vitamins and minerals)
  61. Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of the randomization visit
  62. Requirement for continuous use of any medications or treatments prohibited in the study
  63. Pregnant or breastfeeding, or intending to become pregnant during the treatment period and for at least 3 months after the final intravitreal injection of ranibizumab or aflibercept, or 1 year after the last implant refill-exchange procedure
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    Subjects will have the implant (filled intra-operatively prior to implantation with approximately 20 µL of the 100-mg/mL formulation of ranibizumab \[approximately 2-mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Subjects will have their implant refilled with ranibizumab at weeks 36 and 72.

    Drug: Ranibizumab · Device: Port Delivery System with ranibizumab (PDS)

  • Active comparator
    Aflibercept

    Subjects will receive intravitreal injections of aflibercept (2mg) administered in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment.

    Drug: Aflibercept

Interventions

  • Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.

  • Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment

  • DevicePort Delivery System with ranibizumab (PDS)

    PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.

06

What researchers measure

Primary outcomes

  1. Change from baseline in BCVA score at week 80 as assessed using the ETDRS visual acuity chart at a starting distance of 4 meters

    \*Depending on the T\&E schedule, some subjects in the comparator arm will have a visit at Week 76 and some at Week 78. All subjects in both arms will have a Week 80 visit

    Time frame: From baseline up to 80 weeks

  2. Treatment burden as assessed by the treatment frequency up to Week 80

    Treatments include injections and refills.

    Time frame: From baseline up to 80 weeks

Secondary outcomes

  1. Proportion of subjects with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better averaged over Weeks 76 (or 78*) and 80

    \*Depending on the T\&E schedule, some subjects in the comparator arm will have a visit at Week 76 and some at Week 78. All subjects in both arms will have a Week 80 visit

    Time frame: Baseline, Week 76, Week 78, Week 80

  2. Proportion of subjects with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse averaged over Weeks 76 (or 78*) and 80

    \*Depending on the T\&E schedule, some subjects in the comparator arm will have a visit at Week 76 and some at Week 78. All subjects in both arms will have a Week 80 visit

    Time frame: Baseline, Week 76, Week 78, Week 80

  3. Proportion of subjects who lose < 15, < 10, or < 5 letters in BCVA score from baseline averaged over Weeks 76 (or 78*) and 80

    \*Depending on the T\&E schedule, some subjects in the comparator arm will have a visit at Week 76 and some at Week 78. All subjects in both arms will have a Week 80 visit

    Time frame: Baseline, Week 76, Week 78, Week 80

  4. Change from baseline in center point thickness (CPT) at Week 80

    \*CPT defined as the retinal thickness in the center point of the fovea measured between the internal limiting membrane and the inner third of the retinal pigment epithelium layer, on spectral-domain optical coherence tomography (SD-OCT)

    Time frame: Baseline, Week 80

  5. Change from baseline in center subfield thickness (CST), defined as the average thickness of the central 1 mm circle of the ETDRS grid centered on the fovea measured between the internal limiting membrane and the Bruch's membrane, on SD-OCT at Week 80

    Time frame: Baseline, Week 80

  6. Proportion of subjects randomized to PDS Q36W who do not undergo supplemental treatment with intravitreal ranibizumab 0.5 mg before each refill-exchange procedure

    Time frame: Baseline, Week 80

  7. Incidence and severity of ocular and systemic (non-ocular) adverse events

    Time frame: Baseline, Week 80

  8. Incidence, severity, and duration of adverse events of special interest, including ocular adverse events of special interest

    Time frame: Baseline, Week 80

  9. Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (≤ 37 days of initial implantation) and follow-up period (> 37 days after implantation surgery)

    Time frame: Baseline, Week 80

  10. Incidence and severity of adverse device effects with PDS Q36W

    Time frame: Baseline, Week 80

  11. Incidence, causality, severity, and duration of anticipated serious adverse device effects with PDS Q36W

    Time frame: Baseline, Week 80

07

Study locations

10 sites
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Rigshospitalet Glostrup; Afdeling for Øjensygdomme
    Glostrup, 2600, Denmark
  • Sjællands Universitetshospital, Roskilde; Øjenafdelingen
    Roskilde, 4000, Denmark
  • University Hospital of Larissa; Department of Ophthalmology
    Larisa, 412 21, Greece
  • Queen Mary Hospital; Department of Ophthalmology
    Hong Kong, Hong Kong
  • Hong Kong Eye Hospital; CUHK Eye Centre
    Mongkok, Hong Kong
  • Hospital de Sao Joao; Servico de Oftalmologia
    Porto, 4200-319, Portugal
  • Hospital de la Arruzafa. Servicio de Oftalmologia
    Cordoba, 14012, Spain
  • King Chulalongkorn Memorial Hospital; Ophthalmology Department
    Bangkok, 10330, Thailand
  • Maharaj Nakorn ChiangMai Hospital; Ophthalmology Department
    ChiangMai, 50200, Thailand
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2023; primary completion for Jan 2025, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Nov 19, 2021
StartEst.
Dec 29, 2023
Primary completionEst.
Jan 31, 2025
CompletionEst.
Jan 30, 2026
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05126966
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Dec 29, 2023 (estimated)
Primary completion
Jan 31, 2025 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Jan 18, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion